Key players of neuroendocrine differentiation in prostate cancer

Affiliations

¹ Oncology Unit, Macerata Hospital, Macerata, Italy.
² Medical Oncology Division of Urogenital and Head and Neck Tumours, IEO, European Institute of Oncology IRCCS, Milan, Italy.
³ Direzione Area Vasta 3-ASUR, Marche, Italy.

Editorial

Matteo Santoni et al. Ann Transl Med. 2019 Jul.

. 2019 Jul;7(Suppl 3):S112.

doi: 10.21037/atm.2019.05.18.

¹ Oncology Unit, Macerata Hospital, Macerata, Italy.
² Medical Oncology Division of Urogenital and Head and Neck Tumours, IEO, European Institute of Oncology IRCCS, Milan, Italy.
³ Direzione Area Vasta 3-ASUR, Marche, Italy.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Increased Serine and One-Carbon Pathway Metabolism by PKCλ/ι Deficiency Promotes Neuroendocrine Prostate Cancer.
Reina-Campos M, Linares JF, Duran A, Cordes T, L'Hermitte A, Badur MG, Bhangoo MS, Thorson PK, Richards A, Rooslid T, Garcia-Olmo DC, Nam-Cha SY, Salinas-Sanchez AS, Eng K, Beltran H, Scott DA, Metallo CM, Moscat J, Diaz-Meco MT. Reina-Campos M, et al. Cancer Cell. 2019 Mar 18;35(3):385-400.e9. doi: 10.1016/j.ccell.2019.01.018. Epub 2019 Feb 28. Cancer Cell. 2019. PMID: 30827887 Free PMC article.

1. Reina-Campos M, Linares JF, Duran A, et al. Increased Serine and One-Carbon Pathway Metabolism by PKCλ/ι Deficiency Promotes Neuroendocrine Prostate Cancer. Cancer Cell 2019;35:385-400.e9. 10.1016/j.ccell.2019.01.018 - DOI - PMC - PubMed
1. Montironi R, Santoni M, Lopez-Beltran A, et al. Morphologic and molecular backgrounds for personalized management of genito-urinary cancers: an overview. Curr Drug Targets 2015;16:96-102. 10.2174/1389450115666141202113805 - DOI - PubMed
1. Santoni M, Scarpelli M, Mazzucchelli R, et al. Current Histopathologic and Molecular Characterizations of Prostate cancer: Towards Individualized Prognosis and Therapies. Eur Urol 2016;69:186-90. 10.1016/j.eururo.2015.05.041 - DOI - PubMed
1. Ciccarese C, Santoni M, Massari F, et al. Present and future of personalized medicine in adult genitourinary tumors. Future Oncol 2015;11:1381-8. 10.2217/fon.15.30 - DOI - PubMed
1. Ciccarese C, Santoni M, Brunelli M, et al. AR-V7 and prostate cancer: The watershed for treatment selection? Cancer Treat Rev 2016;43:27-35. 10.1016/j.ctrv.2015.12.003 - DOI - PubMed